Prescient Therapeutics Within All Ordinaries Biotechnology Landscape
Prescient Therapeutics advanced clinical biotechnology activity through European regulatory authorisations while maintaining participation within the...
Prescient Therapeutics advanced clinical biotechnology activity through European regulatory authorisations while maintaining participation within the...
Prescient Therapeutics Ltd (ASX: PTX) reported meaningful regulatory progress during the December 2025 quarter, with...
Prescient Therapeutics Ltd (ASX: PTX) earlier this week received European authorisation to begin clinical trials...
As the Wise Man sayeth, one should giveth a task to a busy person if...
Special Report: Prescient Therapeutics has raised $3m in a placement to sophisticated and professional investors following...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) on Wednesday issued results for the June quarter highlighting the first...
Prescient Therapeutics has entered a critical stage where clinical data, regulatory support, and commercial potential...
In a sector where the right drug emerging at the right time can yield billions, Prescient...
Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug...
While part of the story is an increased ability to diagnose cancers early, thanks to...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.